NasdaqCM:TGTXBiotechs
How Investors Are Reacting To TG Therapeutics (TGTX) New BRIUMVI Real-World Data And Pediatric Trials
TG Therapeutics recently presented new data on its marketed multiple sclerosis therapy BRIUMVI at the ACTRIMS annual forum in San Diego, including findings from the ENABLE real-world study in adults with relapsing MS.
The company also highlighted ongoing Phase 2 and Phase 3 trials of ublituximab in children and adolescents, underscoring its push to extend BRIUMVI’s clinical footprint across age groups.
Next, we’ll examine how this fresh real-world BRIUMVI evidence shapes TG Therapeutics’...